Alaunos Therapeutics, Inc. (TCRT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.88. The rating moved from Overbought to Oversold on August 15, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$1.88
• Last changeMoved from Overbought to Oversold on August 15, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company with value largely tied to the progress of early-stage programs and potential partner or regulatory catalysts. The company lacks commercial revenue and is vulnerable to dilution if additional capital is needed; therefore near-term outlook hinges on data progress and financing strategy. Market conditions show a modest risk-on bias for growth and biologics which may help with partnering interest, but limited liquidity and high binary clinical risk make near-term price action unpredictable. Watch upcoming clinical milestones, cash runway disclosures, and any collaboration announcements as the primary determinants of the company’s trajectory.

Key factors

• Clinical-stage therapeutic portfolio with lead programs that could drive binary near-term catalysts (trial readouts, INDs, or partnerships).
• No meaningful commercial revenue; performance and valuation are highly dependent on R&D progress and capital markets access.
• Sector environment: constructive biotech flows and demand for biologics/CDMO services could indirectly support valuation and partnering opportunities.
• Corporate governance and potential for strategic moves (collaborations, licensing) could materially de-risk programs if executed.
• Small-cap illiquidity and sensitivity to macro risk appetite make share price prone to sharp swings around news.

Risks

• Clinical trial failure, unexpected safety signals, or missed endpoints for lead candidates.
• Limited cash runway requiring equity raises that dilute existing shareholders and pressure the share price.
• Regulatory delays or more onerous approval pathways for the target indications.
• Competition from larger, better-funded biopharma companies and alternative therapeutic modalities.
• Low analyst coverage and thin trading liquidity increasing volatility and the potential for exaggerated moves on limited news.

Latest MarketMoodz coverage

• Alaunos' Obesity Data Shows Promise in Mice, Shares Dip2026-03-02

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.